The role of gut microbiota on the tumor microenvironment in colorectal cancer: a systematic review and meta-analysis.
Abstract
Background
This meta-analysis and systematic review examined gut microbial metabolites and the tumor microenvironment (TME) in colorectal cancer (CRC), as well as the influence of microbial metabolites on cancer development and treatment. The focus was on explaining how microbial metabolites influence cancer development and treatment outcome.
Methods
A systematic search of PubMed, Embase, and the Cochrane Library was conducted (January 2010-December 2020) following the PRISMA 2020 guidelines.
Results
Literature search yielded 765 articles, from which 22 studies were identified as meeting inclusion criteria after stringent screening. Included studies encompassed in vitro, in vivo, and patient-derived data on the role of gut microbial metabolites (e.g., short-chain fatty acids [SCFAs], bile acids, polyamines, and trimethylamine-N-oxide) in characterizing the CRC TME. Meta-analysis found that SCFAs, particularly butyrate, consistently played protective and regulatory functions, suppressing inflammation and stimulating antitumor immunity. In contrast, bile acids and certain microbial populations (e.g., Fusobacterium nucleatum) were associated with tumor-promoting pathways, including NF-κB and STAT3 activation. The overall result was moderately heterogeneous (I2=40%, P<0.05), reflecting variability in study design and metabolite focus. Publication bias testing with Egger's regression and funnel plots showed no indication of large small-study effects (P=0.21). Overall, 59% of studies reviewed cited a positive or modulatory function of metabolites in the TME, 27% proposed context-dependent or mixed effects, and 14% exhibited tumor-promoting activities. Moderate evidence strength, with limitations by virtue of preclinical and observational evidence, was present. Gut microbiota metabolites have context-dependent roles in CRC, SCFAs tending to be protective, and bile acids typically tumor-promoting.
Conclusions
The findings exhibit the therapeutic promise of microbiome-targeting treatments and dietary manipulation in modifying the TME. However, they remain to be confirmed by follow-up large-scale clinical trials to consolidate the evidence base.